TY - JOUR
T1 - Durability of Antibody Response and Frequency of SARS-CoV-2 Infection 6 Months after COVID-19 Vaccination in Healthcare Workers
AU - Laing, Eric D.
AU - Weiss, Carol D.
AU - Samuels, Emily C.
AU - Coggins, Si'Ana A.
AU - Wang, Wei
AU - Wang, Richard
AU - Vassell, Russell
AU - Sterling, Spencer L.
AU - Tso, Marana S.
AU - Conner, Tonia
AU - Goguet, Emilie
AU - Moser, Matthew
AU - Jackson-Thompson, Belinda M.
AU - Illinik, Luca
AU - Davies, Julian
AU - Ortega, Orlando
AU - Parmelee, Edward
AU - Hollis-Perry, Monique
AU - Maiolatesi, Santina E.
AU - Wang, Gregory
AU - Ramsey, Kathleen F.
AU - Reyes, Anatalio E.
AU - Alcorta, Yolanda
AU - Wong, Mimi A.
AU - Lindrose, Alyssa R.
AU - Duplessis, Christopher A.
AU - Tribble, David R.
AU - Malloy, Allison M.W.
AU - Burgess, Timothy H.
AU - Pollett, Simon D.
AU - Olsen, Cara H.
AU - Broder, Christopher C.
AU - Mitre, Edward
N1 - Funding Information:
Defense Health Program and the CARES Act (grant nos. HU00012120067, HU00012120104, and HU00012120094) and the National Institute of Allergy and Infectious Disease (grant no. HU00011920111). The protocol was executed by the Infectious Disease Clinical Research Program, a US Department of Defense program executed by the Uniformed Services University of the Health Sciences through a cooperative agreement by the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. This project has been funded in part by the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (interagency agreement no. Y1-AI-5072).
Funding Information:
This work was supported by awards from the
Publisher Copyright:
© 2022 Centers for Disease Control and Prevention (CDC). All rights reserved.
PY - 2022/4
Y1 - 2022/4
N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies decay but persist 6 months postvaccination; lower levels of neutralizing titers persist against Delta than wild-type virus. Of 227 vaccinated healthcare workers tested, only 2 experienced outpatient symptomatic breakthrough infections, despite 59/227 exhibiting serologic evidence of SARS-CoV-2 infection, defined as presence of nucleocapsid protein antibodies.
AB - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies decay but persist 6 months postvaccination; lower levels of neutralizing titers persist against Delta than wild-type virus. Of 227 vaccinated healthcare workers tested, only 2 experienced outpatient symptomatic breakthrough infections, despite 59/227 exhibiting serologic evidence of SARS-CoV-2 infection, defined as presence of nucleocapsid protein antibodies.
UR - http://www.scopus.com/inward/record.url?scp=85127183262&partnerID=8YFLogxK
U2 - 10.3201/eid2804.212037
DO - 10.3201/eid2804.212037
M3 - Article
C2 - 35203111
AN - SCOPUS:85127183262
SN - 1080-6040
VL - 28
SP - 828
EP - 832
JO - Emerging Infectious Diseases
JF - Emerging Infectious Diseases
IS - 4
ER -